Cancer risk in Korean patients with gout
- Author:
Yoon-Jeong OH
1
;
Yun Jong LEE
;
Eunyoung LEE
;
Bumhee PARK
;
Jae-Woo KWON
;
Jeongwon HEO
;
Ki Won MOON
Author Information
- Publication Type:2
- From:The Korean Journal of Internal Medicine 2022;37(2):460-467
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:Using a nationwide cohort, we investigated the cancer risk in Korean patients with gout.
Methods:Data were obtained from the Korean National Health Insurance Service Database. Patients with gout were defined as those aged ≥ 20 years who were diagnosed with gout and received anti-gout medication (allopurinol, colchicine, and benzbromarone) between 2008 and 2010. Patients with nail disorders were randomly assigned to a control group (1:1 ratio) after frequency matching for age and sex. Cancer incidence was then investigated between 2012 and 2018. Cox proportional hazard regression analysis was used to investigate the association between gout and cancer after adjusting for concomitant diseases.
Results:This study included 179,930 patients with gout and an equal number of matched controls. The incidence of overall cancer was higher in patients with gout than in controls (incidence rate ratio, 1.08). Cox proportional hazards regression analysis showed that gout was associated with a hazard ratio of 1.053 (95% confidence interval ,1.031 to 1.077) after adjusting for concomitant diseases.
Conclusions:Gout was associated with a significantly high risk of cancer, especially esophageal, stomach, colon, liver, pancreatic, lung, ovarian, renal, and bladder cancers.
